嗓音基频变化与他汀类药物治疗

文献信息

中文摘要

目的： 他汀类药物被认为是血脂异常的一线治疗药物，也是全球最常处方的药物。然而，他汀类药物治疗与多种不良反应相关，包括他汀相关性肌病，后者可表现为肌痛、肌肉僵硬和痉挛等症状。由于发声涉及喉部骨骼肌，他汀相关的肌肉效应也可能影响嗓音功能。嗓音基频（FFF）取决于声带长度、质量和张力，因此可能反映喉部肌肉功能的改变。
设计： 在这项前瞻性观察性研究中，作者分析了基线时（T0，开始他汀类药物治疗前）以及治疗3个月后（T1）的FFF。为测量FFF，我们使用了灵敏麦克风和多维嗓音程序。
参与者： 最初纳入36例成年患者（16例男性，20例女性），其中28例成功完成研究（12例男性，16例女性）。
结果： 在完成3个月研究的28例患者中，20例出现FFF降低。其中，14例出现轻度肌肉痉挛，而6例未出现任何症状。
结论： 在接受他汀类药物治疗的部分患者中观察到基频变化。这些发现提示，声学嗓音分析可能反映他汀治疗期间喉部肌肉功能的改变。然而，鉴于样本量有限且缺乏对照组，需要更大队列并控制混杂因素的前瞻性研究来阐明FFF作为他汀相关性肌病客观标志物的潜在作用。

英文摘要

OBJECTIVES: Statins are considered a first-line treatment for dyslipidaemia, being the most frequently prescribed medicine worldwide. However, statin therapy has been associated with several adverse effects, including statin-associated myopathy, which may manifest with symptoms such as myalgia, muscle stiffness, and cramps. Because phonation involves skeletal muscles of the larynx, statin-related muscular effects may also influence vocal function. The fundamental frequency of the voice (FFF) depends on vocal fold length, mass, and tension and may therefore reflect alterations in laryngeal muscle function.
DESIGN: In this prospective observational study, the authors analysed the FFF at the baseline (T0), before initiating statin therapy, and after 3 months of treatment (T1). To measure the FFF, we have used a sensible microphone and the Multi-Dimensional Voice Program.
PARTICIPANTS: Thirty-six adult patients (16 men and 20 women) have been initially enrolled, 28 of whom have successfully completed the study (12 men and 16 women).
RESULTS: Among the 28 patients who have completed the 3 months' study, 20 have had a reduction of the FFF. Of these, 14 have experienced mild muscle cramps, whereas 6 of them have not experienced any symptoms.
CONCLUSION: Changes in fundamental frequency were observed in a proportion of patients undergoing statin therapy. These findings suggest that acoustic voice analysis may potentially reflect alterations in laryngeal muscle function during statin treatment. However, given the limited sample size and the absence of a control group, further prospective studies with larger cohorts and controlled confounding factors are necessary to clarify the potential role of FFF as an objective marker of statin-associated myopathy.